NAD+500mg
NAD+ Canada — 500 mg, 1000 mg Lyophilized Vials
Nicotinamide Adenine Dinucleotide Research Compound
NAD+ is a fundamental coenzyme studied in laboratory research for its central role in cellular energy metabolism and redox reactions. Investigations commonly focus on its involvement in mitochondrial function, enzymatic activity, and broader biochemical pathways related to cellular maintenance and signaling in controlled experimental models.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in all living cells and plays a central role in cellular redox reactions. It is supplied for controlled laboratory research involving metabolic and mitochondrial signaling systems.
In scientific literature, NAD+ is studied in experimental models examining oxidative phosphorylation, sirtuin-associated pathways, and cellular energy regulation mechanisms under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
NAD+ is a fundamental coenzyme involved in redox reactions, cellular respiration, and energy metabolism research. Experimental studies examine its role in mitochondrial function models, sirtuin-related signaling pathways, and oxidative stress response systems within controlled laboratory environments.
Preclinical and biochemical research publications have explored its involvement in metabolic regulatory frameworks and enzymatic signaling cascades.
NAD+ was first identified in the early 20th century during investigations into fermentation and cellular respiration. Over time, it became recognized as a critical cofactor in metabolic reactions and enzymatic processes.
Subsequent research expanded into studies of its role in mitochondrial function, energy metabolism, and cellular regulatory systems within experimental models.
Laboratory investigations into NAD+ have focused on cellular energy metabolism models, mitochondrial signaling pathways, and redox-regulated enzymatic systems. Research frameworks evaluate its role in sirtuin activation models, oxidative phosphorylation systems, and metabolic regulatory mechanisms under controlled in vitro and preclinical conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Ying 2006. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Ying 2006. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on sirtuin. This heading marks where NAD+ is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
No paper cited on this page reports on metabolic. This heading marks where NAD+ is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 2006 and 2016 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
NAD+ is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for NAD+, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
NAD+ is also referred to as NAD+, NAD plus.
NAD+ is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under cellular redox reaction models, mitochondrial function research and sirtuin-related signaling pathway studies.
The 3 papers cited on this page, published between 2006 and 2016 (1 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for NAD+ is per lot, not per product. Across the strengths currently stocked: 500mg lot NAD-CA-26F-500 returned 512.17 mg measured, 102.4% of the labelled 500 mg; 1000mg lot NAD-CA-26I-1000 returned 1046.68 mg measured, 104.7% of the labelled 1000 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is NAD+; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for NAD+, across the strengths stocked they run from 102.4% to 104.7% of label. Both numbers are published for every lot, whichever way they fall.
Each strength of NAD+ carries its own lot code and its own certificate — NAD-CA-26F-500, NAD-CA-26I-1000 are separate tests, not one result applied across the range. The code printed on the vial you receive is the one to match, and matching it is what ties the material in hand to a test that was actually run on it.
Researchers who buy NAD+ in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
NAD+ is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each vial contains 500mg of NAD+. Independent third-party testing verifies purity, identity, and net content per batch.
The vial contains only the compound. Any laboratory materials required for experimental procedures must be sourced separately.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Related
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$144.95CAD
